EU Commission's SCENIHR casts fresh eye over PIP implant safety, MoM hips
This article was originally published in Clinica
SCENIHR, the European Commission’s scientific committee that assesses emerging and newly identified health risks, is to give a second opinion in June on the safety of the controversial PIP silicone gel breast implants. The devices, which were filled with industrial-grade silicone and sold worldwide, became the centre of a public health storm at end of 2011 and threw the medtech industry - and the revision on the medical device directives - into turbulent waters last year.
You may also be interested in...
The EU is pulling out all the stops to have the one-year delay to the MDR adopted before it is too late, and a crucial vote will take place on 16 April.
Virtual notified body audits of medtech manufacturers are already taking place through necessity. Now there is guidance concerning if, when, where and how these audits should be carried out.
Medicinal products authorities will consider a medtech notified body opinion on the device element of a drug/device combination product. A new position paper explains how roles and responsibilities are shared between medtech and medicinal product experts.